ClinicalTrials.gg
RecruitingNCT05956067Updated Nov 2, 2026

Chromatic Retinal Stimulation to Reduce Chronic Pain and Pain Sensitivity

An interventional study of Green Light stimulation and Equal Energy White stimulation in Chronic Low-back Pain, Chronic Pain and Fibromyalgia, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.
Updated Nov 2, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Chronic Pain by University of North Carolina, Chapel Hill — 3 open to participants now, 3 under way, none of them phase 3. Chronic Pain · University of North Carolina, Chapel Hill.

Planned enrollment
11th of 11
20 · median 30
Started
2023
with 2 others
No phase
8 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Chronic Pain by University of North Carolina, Chapel Hill, this one is the 11th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 9th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

3 of the 12 studies in Chronic Pain by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Chronic Pain by University of North Carolina, Chapel Hill, or all of them as a file.
02

Study summary

Participants with chronic pain conditions including chronic low back pain and fibromyalgia may benefit from light stimuli presented to the retina to reduce chronic pain severity and pain sensitivity. Participants will be recruited into this study and will be presented with one of three uniform light stimuli via a wide-field ganzfeld in three conditions to determine the retinal mechanisms that reduce pain. This work will lead to a greater understanding of retinal mechanisms that contribute to pain and will assist the design of future studies to harness the potential of light based pain therapies.

03

Conditions studied

  • Chronic Low-back Pain
  • Chronic Pain
  • Fibromyalgia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults greater than or equal to 18 and less than or equal to 65.
  • Individuals who have been diagnosed with fibromyalgia or chronic low back pain by their physician.
  • Individuals who experience an average pain severity greater than 4/10 in intensity at baseline.
  • Willingness to wear a battery-operated portable ganzfeld light stimulator device for 2 hours per day at the same time each day (ideally complete the light therapy session between 5 am-10 am each morning) for 5 days.
  • Alert and oriented, and able to provide
  • Ability to read and speak English to complete validated questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Vision disorders or conditions resulting in severe vision impairment or blindness
  • Individuals with self-report of color blindness
  • Prisoner Status
  • Pregnancy
  • No other history or condition that would, in the investigator's judgment, indicate that the patient would very likely be non-compliant with the study or unsuitable for the study (e.g., might interfere with the study, confound interpretation, or endanger the patient).
  • History of seizure disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Equal energy white stimulus

    Equal energy white light at 500 lux. The International Commission on Illumination (CIE) coordinates of this light are (x=y=0.33), indicating that the stimulus appears uniformly white which means that the activation of each of the three classes of photoreceptors are equivalent, thus silencing any chromatic opponency. The stimulus will be delivered by a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.

    Device: Equal Energy White stimulation

  • Experimental
    Green light stimulus

    Green light at 500 lux. Participants will view 545 nm green light delivered via a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.

    Device: Green Light stimulation

  • Experimental
    S-cone modulating white light

    The S-cone modulating light stimulus will alternate between two light conditions at 500 lux that will activate the S-cones by about 100x differentially between the two conditions while maintaining the L- an M-cones at constant activation between the two alternating conditions using 427 nm versus 545 nm light. The stimulus will be delivered by a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.

    Device: S-cone modulating white light

Interventions

  • DeviceGreen Light stimulation

    A portable battery-operated ganzfeld light display will be used to deliver green light for 2 hours per day for 5 consecutive days.

  • DeviceEqual Energy White stimulation

    A portable battery-operated ganzfeld light display will be used to deliver white light for 2 hours per day for 5 consecutive days.

  • DeviceS-cone modulating white light

    A portable battery-operated ganzfeld light display will be used to deliver S-cone modulating light for 2 hours per day for 5 consecutive days.

06

What researchers measure

Primary outcomes

  1. Feasibility: Percent follow-up

    Percent follow-up for 1 week baseline visit. Follow-up greater than 70% will be considered feasible.

    Time frame: 1 week

  2. Feasibility: Percent of flash surveys completed

    Percent of flash surveys completed during light stimulation period. 0% is the lowest and 100% is the highest. Higher percentages indicate greater percent of flash surveys completed.

    Time frame: 1 week

  3. Feasibility: Self-reported light stimulation sessions completed

    Self-reported light stimulation sessions completed by flash survey administered after each light stimulation session over the 5 day stimulation period. Number of sessions will be reported the minimum is 0 and the maximum is 5.

    Time frame: 1 week

Secondary outcomes

  1. Change in pain intensity after stimulation

    Pain intensity measured by a 0-10 numeric rating scale for overall pain. 0 represents no pain, and 10 represents the worst pain imaginable.

    Time frame: Baseline, 1 week

  2. Change in pressure pain threshold

    Pressure Pain Threshold is the threshold in which pain is experienced in response to increasing force applied to the trapezius measured by a pressure algometer in kilograms of force per square centimeter (kgf/cm\^2). The higher the value, the higher the threshold. The maximum is 10 kgf/cm\^2 and minimum is 0.

    Time frame: Baseline, 1 week

  3. Change in Conditioned Pain modulation

    Conditioned Pain modulation magnitude will be calculated as the difference in mean pressure pain threshold (kgf/cm\^2) measured prior to and during the conditioning stimulus (cold water bath), with increases in pressure pain threshold during conditioning interpreted as evidence of efficient endogenous pain inhibition.

    Time frame: Baseline, 1 week

  4. Change in Temporal Summation

    Temporal Summation. The investigators will evaluate temporal summation using a 40g Neuropen applied to the skin of the volar forearm and lumbar region, following a train of 10 identical stimuli (1 Hz). Participants will report retrospectively, the pain intensity of the 1st and 10th pinprick using a 0-10 numerical rating scale (NRS). 0 is the minimum and 10 is the maximum pain intensity that will be reported.

    Time frame: Baseline, 1 week

  5. Change in activity measured with an accelerometer

    Activity will be measured by an accelerometer. Average daily step count for the duration of the stimulus. Average non-sedentary time in minutes will able be determined over the stimulation period and compared to the data collected over the 1 week run-in period.

    Time frame: 1 week prior to baseline and 1 week during light stimulation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 9 to 18 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available 1 year after completion of the study and will be available for an additional 2 years.

Access criteria: Data use agreement with University before deidentified information requested will be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Oct 2027, 49 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 49 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jul 2026 → Oct 2027 and completion Jul 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2023
First posted
Jul 21, 2023
StartActual
Aug 25, 2023
Primary completionEst.
Oct 1, 2027was Jul 2026
CompletionEst.
Oct 9, 2027was Jul 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Nov 2, 2026
Sites
University Of North Carolina is now Recruiting
Nov 2, 2026
Primary completion
Jul 17, 2026→Oct 1, 2027
Nov 2, 2026
Study completion
Jul 29, 2026→Oct 9, 2027
Nov 2, 2026
Enrollment
60→20
Nov 2, 2026
Contact
Study contact now listed: added m•••@med.unc.edu · •••5136. See the current contact
Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University Of North Carolina · Chapel Hill, United StatesContact added m•••@med.unc.edu · •••5136Contact added (no phone or email listed)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    University Of North Carolina is now Recruiting
    Primary completion Jul 17, 2026→Oct 1, 2027
    Study completion Jul 29, 2026→Oct 9, 2027
    Enrollment 60→20
    Contact Study contact now listed: added m•••@med.unc.edu · •••5136. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University Of North Carolina · Chapel Hill, United StatesContact added m•••@med.unc.edu · •••5136Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05956067
Responsible party
Sponsor
First posted
Jul 21, 2023
Start date
Aug 25, 2023
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 9, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Matthew C Mauck, MD, PhD
Contact
matt_mauck@med.unc.edu
919-966-5136
Matthew C Mauck, MD, PhD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion